China Medical System Holdings Limited
0867
Classificação em ações
#4687
Established in 1995 and headquartered in North Point, Hong Kong, China Medical... Established in 1995 and headquartered in North Point, Hong Kong, China Medical System Holdings Limited functions as an investment holding company with a primary focus on the development, marketing, and distribution of a wide array of pharmaceutical products throughout the People's Republic of China. The company's extensive portfolio addresses numerous therapeutic areas. Its cardiovascular offerings include Plendil for hypertension and stable angina, XinHuoSu for acute heart failure, and Imdur for coronary heart disease, chronic heart failure, and myocardial infarction prevention. For mental health and neurological support, it provides Deanxit to treat mild-to-moderate depression and anxiety, along with Parlodel tablets for endocrine and neuro system indications. Digestive and liver conditions are managed with products such as Ursofalk for gallstones and cholestatic liver disease, Salofalk for ulcerative colitis and Crohn's disease, Bioflor for diarrhea, Combizym for dyspepsia, and Ganfule capsules for primary liver cancer, plus MOVICOL for chronic constipation. The company also markets Augentropfen Stulln Mono eye drops for senile macula degeneration and asthenopia, Hirudoid for blunt trauma and superficial phlebitis, Elcatonin injection for osteoporosis, and Lamisil tablets for fungal infections. Respiratory issues are addressed by YiNuoShu, while infectious diseases benefit from DanShenTong capsules (for various infections like acne, tonsillitis, and boils) and YinlianQinggan granules for hepatitis. XiDaKang, a protein hydrolysate oral solution, is also part of its offerings. Beyond its pharmaceutical endeavors, the group is also actively involved in agriculture and livestock operations. China Medical System Holdings Limited operates as a subsidiary of Treasure Sea Limited.
Preço da ação
$1.33
Valor de mercado
$3.23B
Variação (1 dia)
1.76%
Variação (1 ano)
-22.91%
País
HK
Negociar China Medical System Holdings Limited (0867)
Categoria
Healthcare
Lucros da China Medical System Holdings Limited (0867)
Lucros em Jun 2026 TTM: $309.11M
De acordo com os últimos relatórios financeiros da China Medical System Holdings Limited, os ganhos atuais da empresa são de $309.11M. Em 2023, a empresa teve ganhos de $405.98M, uma diminuição em relação a aos ganhos de 2022, que foram de $545.51M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da China Medical System Holdings Limited de 2006 a 2026
Lucros no final de cada ano
| Ano | Lucros | Alterar |
|---|---|---|
| 2026 (TTM) | $309.11M | 12.23% |
| 2024 | $275.42M | -32.16% |
| 2023 | $405.98M | -25.58% |
| 2022 | $545.51M | 0.31% |
| 2021 | $543.84M | 26.16% |
| 2020 | $431.08M | 20.66% |
| 2019 | $357.26M | 22.48% |
| 2018 | $291.68M | 4.94% |
| 2017 | $277.96M | 28.62% |
| 2016 | $216.11M | 31.88% |
| 2015 | $163.86M | -10.14% |
| 2014 | $182.36M | 64.80% |
| 2013 | $110.65M | 17.00% |
| 2012 | $94.57M | 39.34% |
| 2011 | $67.87M | 95.03% |
| 2010 | $34.80M | 29.24% |
| 2009 | $26.93M | 37.84% |
| 2008 | $19.54M | 88.74% |
| 2007 | $10.35M | 92.47% |
| 2006 | $5.38M | 0.00% |
Lucros de empresas semelhantes ou concorrentes
| Empresa | Lucros | Diferença de Lucros | País |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 470.84% |
IN
|
